Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders
NCT03278938Phase 4Withdrawn
- Sponsor
- New York State Psychiatric Institute
- Start
- Jun 2012
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bupropion, citalopram in major depressive disorder (MDD), sponsored by New York State Psychiatric Institute. Planned start Jun 2012; status: withdrawn.
02
Drugs
bupropioncitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03278938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278938.